Several studies reported a promising anti-COVID-19 drug candidate, the lipoglycopeptide antibiotic dalbavancin, which directly binds to ACE2 with high affinity and thereby blocks its interaction with the SARS-CoV-2 spike protein in vitro [47,48]. This evidence concerns the gene ACE2 and COVID-19.